Loading...
 
Translate Register Log In Login with facebookLogin and Register

CYP24A1 gene in cancer cells may actually remove vitamin D from the blood – Oct 2012

24-Hydroxylase in Cancer: Impact on Vitamin D-based Anticancer Therapeutics.

J Steroid Biochem Mol Biol. 2012 Oct 8. pii: S0960-0760(12)00200-2. doi: 10.1016/j.jsbmb.2012.09.031
Luo W, Hershberger PA, Trump DL, Johnson CS.
Department of Pharmacology and Therapeutics.

The active vitamin D hormone 1,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)) plays a major role in regulating calcium homeostasis and bone mineralization. 1,25(OH)(2)D(3) also modulates cellular proliferation and differentiation in a variety of cell types. 24-hydroxylase, encoded by the CYP24A1 gene, is the key enzyme which converts 1,25(OH)(2)D(3) to less active calcitroic acid.

Nearly all cell types express 24-hydroxylase, the highest activity being observed in the kidney.

There is increasing evidence linking the incidence and prognosis of certain cancers to low serum 25 (OH)D(3) levels and high expression of vitamin D 24-hydroxylase supporting the idea that elevated CYP24A1 expression may stimulate degradation of vitamin D metabolites including 25-(OH)D(3) and 1,25(OH)(2)D(3).

The over expression of CYP24A1 in cancer cells may be a factor affecting 1,25(OH)(2)D(3) bioavailability and anti-proliferative activity pre-clinically and clinically.

The combination of 1,25(OH)(2)D(3) with CYP24A1 inhibitors enhances 1,25(OH)(2)D(3) mediated signaling and anti-proliferative effects and may be useful in overcoming effects of aberrant CYP24 expression.

PMID: 23059474


See also VitaminDWiki

Image

New title for this page May 2019. caused the visitor count to reset.
There have actually been 3254 visitors to this page since it was originally made

Created by admin. Last Modification: Thursday May 16, 2019 15:59:44 GMT-0000 by admin. (Version 6)
See any problem with this page? Report it (FINALLY WORKS)